Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2133729 | 0.93 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL2133726 | 0.93 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL2129673 | 0.90 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL2129669 | 0.90 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL30324719 | 0.89 | CTSB (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL29991848 | 0.88 | CYP3A4 (0.53) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL22764108 | 0.88 | CYP3A4 (0.53) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL2134261 | 0.88 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL2134254 | 0.88 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL6875717 | 0.88 | ADRB3 (0.42) | ADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2023-03-30 | — | — | US | disclosed |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | ADRB3 3732/4885ADRA2B 4185/4885ADRA2C 3931/4885 |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | ADRB3 3732/4885ADRA2B 4185/4885ADRA2C 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.